The European Medicines Agency (EMA) has initiated an investigation into whether weight loss injections like Ozempic could be linked to a rare type of blindness. The agency’s Pharmacovigilance Risk Assessment Committee (PRAC) is examining medications containing semaglutide due to concerns that they might increase the risk of a rare eye condition called Naion. This follows findings from two recent studies.
Semaglutide is the active ingredient in several medications used to treat diabetes and obesity, such as Ozempic, Rybelsus, and Wegovy. PRAC is evaluating whether patients using these drugs are more likely to develop Naion, a condition that results from reduced blood flow to the optic nerve, leading to vision loss. The EMA noted that people with type 2 diabetes may already be at a higher risk for the condition.
One of the studies, published in the International Journal of Retina and Vitreous, involved Danish researchers who studied all individuals with type 2 diabetes in Denmark over five years. Their research suggested that weekly use of semaglutide independently doubled the risk of Naion. “Given the irreversible nature of Naion, it is crucial to recognize this risk, and future studies should identify high-risk subgroups,” the researchers stated.
Semaglutide has also been linked to other serious side effects. A large-scale study from the University of British Columbia this summer found that the medication was associated with an increased risk of serious gastrointestinal issues, including stomach paralysis, pancreatitis, and intestinal obstruction.
Additionally, research has found a potential connection between semaglutide and increased suicidal thoughts. A study by Northwell Health in New York and the University of Zurich revealed that the drug may disproportionately raise the risk of suicidal ideation, especially in patients treated for depression or anxiety.
The drug could also impact children’s development. Experts at the University of California noted that while Ozempic might benefit severely obese children, it could reduce calorie intake in other young users, potentially hindering their growth, exercise, and development.
